DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Dare Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.71−0.02 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $10.51M
- P/E (TTM)
- –
- Dividend yield
- –
Dare Bioscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Market Cap | $10.79M | $197.05M |
| Enterprise Value | -$1.82M | $106.56M |
| PS Ratio | 7.90 | 3.93 |
Enterprise value
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| EV / Sales | -1.33 | 2.69 |
Income (trailing twelve months)
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Revenue | $1.37M | $57.94M |
| Operating Income | -$11.11M | -$21.44M |
| Net Income | -$10.99M | -$22.46M |
| EBITDA | -$8.98M | -$16.91M |
| EPS (Diluted) | -$0.79 | -$0.83 |
Margins
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Operating Margin | -813.4% | -44.5% |
| Profit Margin | -804.4% | -39.2% |
| EBITDA Margin | -657.3% | -31.3% |
| FCF Margin | -860.6% | -8.85% |
Returns
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Return on Assets (ROA) | -62.2% | -41.0% |
| Return on Capital Employed (ROCE) | -204.0% | -37.8% |
Growth
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -53.1% | 2.25% |
Balance sheet
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $12.62M | $62.42M |
| Net Cash (Debt) | $12.62M | $15.68M |
| Net Cash Per Share | $0.83 | $0.65 |
| Equity (Book Value) | -$560.10K | $48.79M |
| Book Value Per Share | -$0.04 | $1.36 |
| Tangible Book Value | -$560.10K | $23.06M |
| Working Capital | -$236.46K | $75.77M |
Financial position
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Current Ratio | 0.99 | 3.30 |
| Quick Ratio | 0.75 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.29M | -$12.35M |
| Capital Expenditures | -$461.93K | -$1.06M |
| Free Cash Flow | -$11.76M | -$20.28M |
| FCF Per Share | -$0.77 | -$0.41 |
Efficiency
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Revenue Per Employee | $56.91K | $398.96K |
| Profits Per Employee | -$457.80K | -$732.08K |
| Employee Count | 24 | 73 |
Dividends and yields
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -101.8% | -21.2% |
| FCF Yield | -108.9% | -7.64% |
Shares
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 15,289,500 | 59,128,900 |
| Shares Change (YoY) | 65.5% | 11.1% |
| Shares Change (QoQ) | 4.19% | 0.54% |
| Float | 13,853,100 | 48,744,500 |
| Shares Held by Insiders | 9.39% | 11.8% |
| Shares Held by Institutions | 8.51% | 59.4% |
Scores
| Measure | Dare Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | -13.49 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Dare Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.